Urgent.News

What's breaking now, across thousands of outlets.

World

HD Hyundai Heavy hosts US maritime delegation at Ulsan shipyard

HD Hyundai Heavy Industries said Friday a U.S. maritime delegation visited its shipyard to discuss cooperation in shipbuilding, military logistics and port infrastructure. The delegation, led by Mark D. Johnson, deputy administrator of the U.S. Maritime Administration (MARAD), toured the shipyard in Ulsan, about 360 kilometers southeast of Seoul, on Thursday. MARAD, an agency under the U.S.…

HD Hyundai Heavy hosts US maritime delegation at Ulsan shipyard

The U.S. Maritime Administration (MARAD) received a visit from a delegation from HD Hyundai Heavy Industries on Thursday. The delegation, headed by Mark D. Johnson, deputy administrator of MARAD, went to HD Hyundai's shipyard in Ulsan, South Korea, to discuss potential cooperation in shipbuilding, military logistics, and port infrastructure.

MARAD is responsible for overseeing the maritime transport of military supplies during national emergencies and supports port infrastructure development. This visit comes as the United States aims to bolster its domestic shipbuilding industry through its Bridge Strategy, which leverages the expertise and production capacity of allies, including South Korea, while expanding its own industrial base.

In a related development, HD Hyundai recently signed a pact with U.S. engineering and construction firm Kiewit to establish a joint venture for building a shipyard in the United States. Construction of this facility is set to commence next year, with full-scale operations anticipated to begin in 2029.

Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at koreatimes.co.kr →

More in World

German Court Overturns Keytruda SC Sales Ban, Opening Door to European Expansion

The path to market entry in Germany, Europe’s largest pharmaceutical market, has opened for Keytruda SC, the subcutaneous formulation of the immuno-oncology drug developed by U.S.-based Merck (MSD)…

  • German court overturns ban on Keytruda SC sales, allowing European expansion.
  • Merck wins patent disputes in Germany and U.S., clearing path for drug's entry.
  • Keytruda SC's subcutaneous formulation reduces treatment time to one to two minutes.

More from Friday 20 November →